The data showed a trend for piperacillin/tazobactam used to be associated with increases in both 14-day and 30-day mortality, although these were not significant.
← all excerpts
Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents.
1
—
—